Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/11058
Full metadata record
DC FieldValueLanguage
dc.contributor.authorArnolda, Len
dc.contributor.authorMcGrath, B Pen
dc.contributor.authorJohnston, Colin Ien
dc.date.accessioned2015-05-16T00:38:13Z
dc.date.available2015-05-16T00:38:13Z
dc.date.issued1991-01-01en
dc.identifier.citationCardiovascular Research; 25(1): 68-72en
dc.identifier.govdoc2054832en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/11058en
dc.description.abstractVasopressin, like angiotensin, has both vasoconstrictor and fluid retaining properties and therefore may make an important contribution to the pathogenesis of low output congestive heart failure. The study aimed to examine the relative importance of the renin-angiotensin system and vasopressin in an animal model of heart failure.The acute haemodynamic effects of vasopressin receptor blockade with a selective antagonist, d(CH2)5DAVP (AVPA) (30 micrograms.kg-1) and angiotensin converting enzyme inhibition with captopril (1 mg.kg-1) were compared. The effect of combined blockade (ie, vasopressin receptor antagonist + angiotensin converting enzyme inhibitor) was also examined.Rabbits, 2.5-3.5 kg, with doxorubicin induced cardiomyopathy and heart failure (n = 20) were used. There were 15 controls.Both AVPA and captopril produced significant increases in cardiac output (11% and 13% respectively) and falls in peripheral vascular resistance (21% and 17% respectively). Inhibition of the two vasoconstrictor systems was additive and resulted in a fall in peripheral vascular resistance to levels found in normal animals.Vasopressin and angiotensin II make equal contributions to the raised peripheral vascular resistance observed in this model of heart failure. Vasopressin inhibition may be useful in the treatment of heart failure either alone or as an adjunct to angiotensin converting inhibition.en
dc.language.isoenen
dc.subject.otherAngiotensin II.physiologyen
dc.subject.otherAnimalsen
dc.subject.otherArginine Vasopressin.analogs & derivatives.pharmacologyen
dc.subject.otherBlood Pressure.drug effectsen
dc.subject.otherCaptopril.pharmacologyen
dc.subject.otherCardiac Output.drug effectsen
dc.subject.otherDisease Models, Animalen
dc.subject.otherFemaleen
dc.subject.otherHeart Failure.physiopathologyen
dc.subject.otherMaleen
dc.subject.otherRabbitsen
dc.subject.otherVascular Resistance.drug effects.physiologyen
dc.subject.otherVasopressins.antagonists & inhibitors.physiologyen
dc.titleVasopressin and angiotensin II contribute equally to the increased afterload in rabbits with heart failure.en
dc.typeJournal Articleen
dc.identifier.journaltitleCardiovascular researchen
dc.identifier.affiliationMelbourne University Department of Medicine, Austin Hospital, Victoria Australiaen
dc.description.pages68-72en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/2054832en
dc.type.austinJournal Articleen
item.grantfulltextopen-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeJournal Article-
item.fulltextWith Fulltext-
item.cerifentitytypePublications-
Appears in Collections:Journal articles
Files in This Item:
File Description SizeFormat 
2054832.pdf432.36 kBAdobe PDFThumbnail
View/Open
Show simple item record

Download(s)

46
checked on Feb 6, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.